DISCOUNT CALL-OPTIONSSCHEIN - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000PC790Z3

Market Closed - Börse Stuttgart 01:09:33 27/05/2024 pm IST
2.32 EUR +3.11% Intraday chart for DISCOUNT CALL-OPTIONSSCHEIN - FRESENIUS MEDICAL CARE
Current month+7.41%
1 month+16.00%
Date Price Change
27/24/27 2.32 +3.11%
24/24/24 2.25 -0.44%
23/24/23 2.26 -3.00%
22/24/22 2.33 -6.05%
21/24/21 2.48 -6.06%

Delayed Quote Börse Stuttgart

Last update May 27, 2024 at 01:09 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC790Z
ISINDE000PC790Z3
Date issued 12/04/2024
Strike 40
Maturity 21/03/2025 (298 Days)
Parity 1 : 1
Emission price 1.35
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.69
Lowest since issue 1.42

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
38.77 EUR
Average target price
39.84 EUR
Spread / Average Target
+2.77%
Consensus